New White Paper: When and How to Use Tumor Organoids in Drug Discovery

Compare the key benefits and applications of tumor organoids alongside conventional 2D and 3D platforms

The clinical relevance of in vitro oncology platforms needs to be improved, to enable better decision making early in the drug development process. 3D in vitro systems have many benefits compared with standard 2D platforms, including more faithfully recapitulating the original tumor architecture which influences drug response.

Within 3D in vitro oncology platforms, tumor organoids offer a new and revolutionary approach. These highly translatable models show unprecedented patient response predictivity combined with the flexibility and scalability for high throughput use. This White Paper reviews the key benefits and applications of in vitro oncology systems, and discusses the optimal ways to utilize tumor organoids alongside conventional platforms.

Download This White Paper to Understand:

• The key differentiators between in vitro systems, including conventional 2D platforms, 3D cultures including patient-derived models, and tumor organoids
  
  
• How to select the right 3D in vitro platform for each stage of your drug development program based on model features, benefits, and limitations
  
  
• How tumor organoids provide a superior and predictive research system for oncology drug development applications
  
  
• The main applications of tumor organoids including high throughput screening, immunotherapy assessment, and enhanced in vivo model selection

Download Now!